

# Index

---

- acetylcholine (ACh) 150
  - quantal release 150–1
    - acquired neuromyotonia 160
    - Lambert–Eaton myasthenic syndrome 151–2, 153
- acetylcholine receptors (AChR) 167–8
  - accelerated degradation 170–1
  - antibodies, *see* anti-acetylcholine receptor (AChR) antibodies
  - (AChR) antibodies
  - antibody binding sites 172–3
  - blockade 171, 223–5
  - extrajunctional 168
  - immunotoxins 191
  - main immunogenic region (MIR) 172–3
  - myasthenia gravis 166–7
  - myosin cross-reactivity 225–8
  - T cell-mediated autoimmune responses 174–5, 176, 221–3
- active zone particles (AZP) 150
  - Lambert–Eaton myasthenic syndrome 151, 152, 153–4
- acute inflammatory demyelinating polyneuropathy, *see* Guillain–Barré syndrome
- acute motor axonal neuropathy 38, 50
- acute pandysautonomia 37
- $\omega$ -aga-toxin 157
- AIDS 255
  - myopathies, *see* HIV myopathy
  - neuropathies, *see* HIV neuropathies
  - subclinical neuromuscular involvement 258
- $\beta$ -amyloid protein 246
- anti-acetylcholine receptor (AChR) antibodies 2, 169–74, 209
  - assays 178–9
  - binding sites 172–3
  - blocking 171, 223–5
  - experimental autoimmune myasthenia gravis
    - differing disease-causing potential 217–20
    - helper T cells and 221–3
    - selective expression of disease-causing subset 220–5
    - strain differences 213–17
  - heterogeneity 173, 212–13, 225–8
  - mechanisms of action 170–1
  - myasthenia gravis without 173–4
  - severity of myasthenia gravis and 171–2, 210–12
- antibody-dependent cellular cytotoxicity (ADCC) 60
- anti-cardiolipin antibodies 2
- anti-CD3 monoclonal antibodies 193
- anti-CD4 monoclonal antibodies 118, 136, 193
- anti-cholinesterase agents 179–80
- anti-cholinesterase test 178
- anti-endothelial cell antibodies (AECA) 108–9
- antigen-presenting cells (APC)
  - Guillain–Barré syndrome 62, 66
  - inflammatory myopathies 243–4
  - peripheral nervous system 124–5, 134
  - targeted, myasthenia gravis 194–5
- anti-GM1 antibodies
  - Guillain–Barré syndrome 57, 58–9, 67
  - multifocal motor polyneuropathy 80, 84, 139
- anti-idiotypic antibodies 19, 118
- anti-lymphocyte antibodies 118–19
- anti-myelin antibodies 7–24
  - chronic inflammatory demyelinating polyneuropathy 22–3, 58, 84, 85
  - experimental allergic neuritis 59, 85, 130, 136–7
  - Guillain–Barré syndrome 20–2, 52–60, 138
  - paraproteinaemic polyneuropathy 10–20, 138–9
- anti-myelin-associated glycoprotein (MAG)

## IMMUNOLOGY OF NEUROMUSCULAR DISEASE

- antibodies 11, 74
- heterogeneity 18–19
- paraproteinaemic polyneuropathy with, *see* paraproteinaemic polyneuropathy, with monoclonal IgM/anti-MAG antibodies
- pathogenic role 14–20
- see also* monoclonal IgM
- anti-neutrophil cytoplasmic autoantibodies (ANCA) 109, 118
- anti-platelet agents 118
- autoantibodies 1–2, 124
  - chronic inflammatory demyelinating polyneuropathy 82–4
  - experimental allergic neuritis 136–7
  - see also specific autoantibodies*
- autoimmune diseases 1–4
  - muscle 235–50
  - peripheral nerves 123–39
- autonomic dysfunction
  - chronic inflammatory demyelinating polyneuropathy 75
  - Guillain–Barré syndrome 34–7, 72
  - Guillain–Barré syndrome (GBS)-like disorders 37
  - Lambert–Eaton myasthenic syndrome 148–9
- axonal degeneration
  - experimental allergic neuritis 131, 132
  - Guillain–Barré syndrome 38, 51, 52
  - vasculitic neuropathy 110–11
- azathioprine
  - chronic inflammatory demyelinating polyneuropathy 88, 89
  - inflammatory myopathies 247
  - myasthenia gravis 181, 184–6, 190
  - vasculitis 116
- azidothymidine (AZT; zidovudine)
  - HIV myopathy 247–8, 283
  - myopathy 245, 256, 274–7
  - treatment 283
  - versus HIV myopathy 274, 277
- B cells**
  - dermatomyositis 236
  - targeting, myasthenia gravis therapy 191
  - see also* autoantibodies; humoral mechanisms
- biopsy, nerve 113
- blood–nerve barrier (BNB) 10, 124
  - experimental allergic neuritis 130, 133–4
  - Guillain–Barré syndrome 60, 66
  - passage of monoclonal IgM across 14–16
- bradycardia, Guillain–Barré syndrome 37
- $\alpha$ -bungarotoxin ( $\alpha$ -BuTx) 166, 168
- calcium ( $\text{Ca}^{2+}$ )
  - Lambert–Eaton myasthenic syndrome
    - and 151
    - neuromuscular transmission 150–1
  - calcium channels, voltage-gated (VGCC) 147, 150–1
  - Lambert–Eaton myasthenic syndrome 151, 152, 155–7
- Campylobacter jejuni* 39–40, 57, 67, 68
- capillaries, dermatomyositis 237
- cardiovascular disorders, Guillain–Barré syndrome 35–7
- CD4<sup>+</sup> T cells
  - chronic inflammatory demyelinating polyneuropathy 85
  - depletion 193
  - inflammatory myopathies 236, 243–4
  - myasthenia gravis 174, 175
  - retrovirus-associated myopathy 265, 269, 271
- CD8<sup>+</sup> T cells
  - inflammatory myopathies 237–9, 242–3
  - retrovirus-associated myopathy 263–6, 269, 271
  - vasculitic neuropathy 110
- CD54, *see* intercellular adhesion molecule-1
- CD58 (LFA-3) 241, 242
- CD59 139
- cell-mediated mechanisms
  - autoimmune diseases 2–4, 124–5
  - chronic inflammatory demyelinating polyneuropathy 82
  - experimental allergic neuritis 60–1, 62, 130–4
  - Guillain–Barré syndrome 60–6, 67, 68
  - inflammatory myopathies 237–44
  - myasthenia gravis 174–5, 176
  - vasculitic neuropathy 109–10
  - see also* macrophages; T cells
- children, Guillain–Barré syndrome 50
- Chinese paralytic syndrome (CPS; acute motor axonal neuropathy) 38, 50
- chondroitin sulphate 139
- chronic ataxic sensory neuropathy 75–6
- chronic inflammatory demyelinating polyneuropathy (CIDP) 7, 73–89
  - animal model 123, 129
  - anti-myelin antibodies 22–3, 58, 84, 85
  - autonomic symptoms 75
  - clinical features 73–4
  - diagnosis 73
  - differential diagnosis 74–5
  - electrophysiology 76–81
    - central involvement 80
    - diagnostic criteria 77–9
  - differential diagnosis and prognostic clues 79–80
  - prognostic clues 81
  - HIV infection 74, 278, 282
  - immunopathogenesis 61, 82–5, 137–8
  - magnetic resonance imaging 81

## INDEX

- management 86–9, 284
- pathology 81–2
- prognosis 75
- variants 75–6
- complement
  - chronic inflammatory demyelinating polyneuropathy 84
  - dermatomyositis 236, 237
  - experimental allergic neuritis 134, 137
  - Guillain–Barré syndrome and 60
  - myasthenia gravis 171
  - vasculitis 106, 107, 108
- computed tomography (CT scan), myasthenia gravis 179
- conduction block 41–2
  - chronic inflammatory demyelinating polyneuropathy 77
  - distal 43
  - Guillain–Barré syndrome 48–9
  - intermittent 41–2
  - multifocal 74–5, 80
  - partial 43–4
- conduction, nerve, *see* nerve conduction
- $\mu$ -conotoxin 151
- $\omega$ -conotoxin 155–7
- corticosteroids
  - chronic inflammatory demyelinating polyneuropathy 86, 88
  - Guillain–Barré syndrome 69, 70–1
  - HIV myopathy 283
  - inflammatory myopathies 246–7, 248
  - myasthenia gravis 181–3, 190
  - side-effects 184
  - vasculitis 115–16, 117, 118
- creatine kinase (CK), serum 244–5, 283
- cyclophosphamide
  - chronic inflammatory demyelinating polyneuropathy 88, 89
  - myasthenia gravis 188, 190
  - vasculitis 115–16, 117
- cyclosporin (A)
  - chronic inflammatory demyelinating polyneuropathy 88, 89
  - inflammatory myopathies 247
  - myasthenia gravis 181, 186–8, 190
- cytokines
  - autoimmune diseases of peripheral nerves 133
  - Guillain–Barré syndrome 62–5, 66, 67
  - vasculitis 110
- cytomegalovirus (CMV)
  - P0 glycoprotein homology 68
  - polyradiculoneuropathy 279–80, 284
- cytotoxic T lymphocytes (CTL)
  - inflammatory myopathies 237–9, 242–3
  - retrovirus-associated myopathy 263–5, 266, 273
  - see also* CD8<sup>+</sup> T cells
- demyelinating neuropathies 7–8
  - electrodiagnostic correlates 42–4
  - mechanisms of conduction abnormalities 40–2
  - paraproteinaemic, *see* paraproteinaemic polyneuropathy
  - see also* chronic inflammatory demyelinating polyneuropathy; Guillain–Barré syndrome
- demyelination
  - experimental allergic neuritis 129, 131, 132, 137
  - Guillain–Barré syndrome 51, 52, 54–5
- dermatomyositis (DM) 235, 249–50
  - clinical features 244–5
  - differential diagnosis 246, 247
  - management 246–8
  - pathogenesis 235, 236–7
- diabetic neuropathy 80
- 3,4-diaminopyridine (3,4-DAP) 158
- dideoxycytosine (ddC) 277, 279, 280
- dideoxyinosine (ddI) 279, 280
- ectopic nerve excitation 42
- edrophonium test 149, 178
- eel electric organ 168
- electromyography (EMG)
  - acquired neuromyotonia 158
  - chronic inflammatory demyelinating polyneuropathy 79, 81
  - Guillain–Barré syndrome 47–8, 50, 51
  - inflammatory myopathies 245
  - Lambert–Eaton myasthenic syndrome 149
  - single-fibre 178, 179
  - vasculitic neuropathy 112–13
- electrophysiology
  - chronic inflammatory demyelinating polyneuropathy 76–81
  - demyelinating neuropathies 40–4
  - Guillain–Barré syndrome 44–50
  - see also* electromyography; nerve conduction studies
- endothelial cells
  - monoclonal IgM (M-IgM) interactions 16
  - vasculitis and 109, 110
- endplate potential (EPP) 150–1, 167
- experimental allergic neuritis (EAN) 123, 128–30
  - anti-myelin antibodies 59, 85, 130, 136–7
  - autonomic dysfunction 35
  - chronic relapsing (CREAN) 85, 129
  - humoral mechanisms 136–7
  - immunopathogenesis 133–4
  - T cell-mediated autoimmune responses 60–1, 62, 130, 131–3, 138
  - therapeutic studies 135–6

## IMMUNOLOGY OF NEUROMUSCULAR DISEASE

- experimental autoimmune encephalomyelitis (EAE) 85, 130, 194
- experimental autoimmune myasthenia gravis (EAMG) 2, 3, 165, 169–70, 209–29
  - selective expression of anti-AChR antibody subset 220–5
  - specificity of anti-AChR antibody subsets 217–20
  - strain differences in susceptibility 213–17
- fatigue, myasthenia gravis 167
- Fisher syndrome 38, 50
  - humoral mechanisms 57–9
- focal hypertrophic neuropathy 76
- Forssman antigen 56
- F-waves
  - chronic inflammatory demyelinating polyneuropathy 79, 81
  - Guillain–Barré syndrome 45
- galactocerebroside (GC) 8
  - experimental allergic neuritis and 85, 136–7
  - Guillain–Barré syndrome and 21, 22
- gancyclovir 284
- gangliosides 8–9
  - Guillain–Barré syndrome and 21, 22, 57–60
- genetic factors
  - autoimmune disease 4
  - chronic inflammatory demyelinating polyneuropathy 82
  - myasthenia gravis 177
- glue sniffing 74
- GM1 ganglioside 8
  - antibodies, *see* anti-GM1 antibodies
  - cross-reactive epitopes 68
- graft versus host disease 177
- Guillain–Barré syndrome (GBS) 7, 33–73
  - animal model, *see* experimental allergic neuritis
  - antecedent events 39–40
  - anti-myelin antibodies 20–2, 52–60, 138
  - clinical features 33–7
  - course and prognosis 37–8
  - diagnostic criteria 35
  - differential diagnosis 39, 79
  - electrodiagnostic criteria 44, 48–9
  - electrophysiology 44–50
    - advanced disease 49–50
    - clinical features and 50–1
    - early disease 44–9
    - variants 50
  - HIV infection 277–8
  - immunopathogenesis 52–69, 137–8
    - cellular mechanisms 60–6
    - humoral mechanisms 52–60
    - initiation of immune response 67–9
    - management 69–73, 284
  - pathology 51–2, 53–5
  - prognostic factors 38
  - recurrent 38, 75
  - variants 38, 50
- heat shock proteins (hsp), muscle fibres 240–1
- helper T cells
  - experimental autoimmune myasthenia gravis 221–3
  - see also* CD4<sup>+</sup> T cells
- hereditary motor and sensory neuropathy (HMSN) 74, 79
- herpes simplex virus (HSV) 68, 176
- HIV infection 255
  - myasthenia gravis 258–9
  - myoglobinuria 258
  - polymyositis, *see* HIV myopathy
  - pyomyositis 259, 283–4
  - subclinical neuromuscular involvement 258
- HIV myopathy (polymyositis) 255, 256–8
  - histology 257
  - immunopathogenesis 245, 263–6, 273
  - pathogenesis 259–67
  - subclinical 258
  - treatment 247–8, 281–3
  - versus AZT myopathy 274, 277
  - virological studies in biopsies 259–63
- HIV neuropathies 255, 277–81, 282
  - differential diagnosis 74, 278
  - pathogenesis 281
  - treatment 284
- HIV wasting syndrome 267
- HLA haplotypes
  - chronic inflammatory demyelinating polyneuropathy 82
  - Guillain–Barré syndrome 57–9, 68
  - Lambert–Eaton myasthenic syndrome 151
  - myasthenia gravis 177
  - see also* major histocompatibility complex
- human foamy retrovirus (HFV) 269–72
- human T cell lymphotropic virus I (HTLV-I)
  - myopathy 267–9
  - pathogenesis 245, 268–9, 273
- humoral mechanisms
  - acquired neuromyotonia 160
  - autoimmune disease 1–2, 124
  - criteria 169
  - chronic inflammatory demyelinating polyneuropathy 82–4
  - dermatomyositis 236–7
  - experimental allergic neuritis 136–7
  - Guillain–Barré syndrome 52–60, 66, 67, 68, 138
  - Lambert–Eaton myasthenic syndrome 151–4

## INDEX

- myasthenia gravis 169–74
- vasculitic neuropathy 106–9
- see also* autoantibodies
- 5-hydroxytryptamine (5-HT) 130
- hypersensitivity vasculitides 114–15
- hypertrophic neuropathy, focal 76
  
- immune complexes
  - dermatomyositis 236
  - vasculitic neuropathy 106–8
- immunoglobulin, intravenous, *see*  
  intravenous immunoglobulin
- immunosuppressive therapy
  - chronic inflammatory demyelinating  
  polyneuropathy 88
  - inflammatory myopathies 246–8
  - paraproteinaemic polyneuropathy 13–14
  - vasculitis 115–16
- immunotherapy
  - Guillain–Barré syndrome 69–72
  - myasthenia gravis 181–95
- immunotoxins 19, 191
- inclusion body myositis (IBM) 235, 249–50
  - clinical features 245–6
  - differential diagnosis 246, 247
  - management 246–8
  - pathogenesis 235, 237–40
  - retroviral proteins 273
- infections, muscle 266
- infectious agents 4
  - Guillain–Barré syndrome and 39–40,  
  67–8
  - myasthenia gravis and 176–7
  - myosin cross-reactivity 226
- inflammatory myopathies 235–50
  - clinical features 244–6
  - differential diagnosis 246, 247
  - management 246–8
  - pathogenesis 235–44, 273
  - see also* dermatomyositis; HIV myopathy;  
  human T cell lymphotropic virus I  
  myopathy; inclusion-body myositis;  
  polymyositis
- influenza vaccination 40
- intensive care
  - Guillain–Barré syndrome 72, 73
  - inflammatory myopathies 248
- intercellular adhesion molecule-1 (ICAM-1)  
  61, 136, 241, 242
- interferon- $\gamma$  (IFN- $\gamma$ )
  - experimental allergic neuritis 133
  - Guillain–Barré syndrome 62, 65, 66, 67
  - myoblast/myotube responses 241, 242,  
  243
- interleukin 1 (IL-1) 62, 66, 67
- interleukin 2 (IL-2) toxin 193
- interleukin 6 (IL-6) 62, 66, 67
- intravenous immunoglobulin (IVIG)
  - chronic inflammatory demyelinating  
  polyneuropathy 86, 87, 88–9
  - Guillain–Barré syndrome 69, 71–2
  - HIV myopathy 283
  - inflammatory myopathies 247, 248
  - myasthenia gravis 189–90
  - vasculitis 117–18
- intubation, Guillain–Barré syndrome 72–3
- iodine, radioactive 191
- Isaac’s syndrome, *see* neuromyotonia,  
  acquired
- isoelectric focusing (IEF) 213–14
  - preparative (pIEF) 218–19
  
- L2/HNK-1 epitope 10, 16–18
- Lambert–Eaton myasthenic syndrome  
  (LEMS) 147–58
  - autoimmune basis 151–4, 158
  - clinical features 148–9
  - experimental studies 150–1
  - incidence 148
  - role of small cell lung cancer 154–5
  - sera, effect on cultured cells 155–7
  - treatment 158
- leucocytoclastic reaction 107, 110
- leukaemia, HTLV-I-positive 269, 272
- Lewis rats
  - anti-AChR antibody heterogeneity  
  217–19
  - experimental autoimmune myasthenia  
  gravis 214–17
- LM1 ganglioside 8–9, 56, 57
  - Guillain–Barré syndrome and 58
- lung cancer, small cell (SCLC) 148
  - role in Lambert–Eaton myasthenic  
  syndrome 154–5
  - studies with cultured cells 155–7
  - treatment 158
- lupus erythematosus, systemic (SLE) 2, 3
- Lyme disease 74
- lymphocyte function-associated (LFA)  
  molecule 3 (LFA-3; CD58) 241, 242
  
- macrophages
  - chronic inflammatory demyelinating  
  polyneuropathy 82, 85
  - experimental allergic neuritis 129, 134
  - Guillain–Barré syndrome 52, 54–5, 62–5,  
  66
  - HIV neuropathy 281, 282
  - inflammatory myopathies 236, 238, 239
  - retrovirus-associated myopathies 263,  
  265, 269
  - vasculitic neuropathy 110
- magnesium (Mg<sup>2+</sup>) 151
- magnetically evoked motor potentials 47
- magnetic resonance imaging (MRI)
  - chronic inflammatory demyelinating  
  polyneuropathy 81

## IMMUNOLOGY OF NEUROMUSCULAR DISEASE

- myasthenia gravis 179
- major histocompatibility complex (MHC)
  - class I molecules
    - chronic inflammatory demyelinating polyneuropathy 82
    - inflammatory myopathies 239–40
    - myoblasts/myotubes 241, 242
    - retrovirus-associated myopathies 266, 269, 271, 272, 273
  - class II molecules 124–5, 133, 221
    - chronic inflammatory demyelinating polyneuropathy 82
    - Guillain–Barré syndrome 62, 63–5
    - muscle fibres 243–4
    - myoblasts/myotubes 241, 242, 243
- malignancy
  - demyelinating neuropathies 74
  - myositis and 245
  - see also* lung cancer, small cell
- methotrexate 247
- MHC, *see* major histocompatibility complex
- Miller Fisher syndrome, *see* Fisher syndrome
- miniature endplate potential (MEPP) 150, 151
- mitochondrial dysfunction, AZT myopathy 274–6
- molecular mimicry 4
  - Guillain–Barré syndrome 67–8
  - myasthenia gravis 176–7
  - retrovirus-associated myopathy 273
- monoclonal antibodies, therapeutic
  - experimental allergic neuritis 136
  - myasthenia gravis 193
  - vasculitis 118–19
- monoclonal gammopathies 10, 76
- monoclonal gammopathy of undetermined significance (MGUS) 10, 74
- monoclonal IgM (M-IgM) 10, 11, 138–9
  - deposits 11–12
  - epitope recognized 16–18
  - heterogeneity 18–19
  - main target antigen 19–20
  - passage across blood–nerve barrier 14–16
  - pathogenic role 14–20
  - see also* paraproteinaemic polyneuropathy, with monoclonal IgM (M-IgM)/anti-MAG antibodies
- monocytes
  - Guillain–Barré syndrome 62–5
  - see also* macrophages
- motor deficits, paraproteinaemic polyneuropathy 11
- motor nerve terminal 147–61
- motor neuropathy, multifocal, with persistent conduction block, *see* multifocal motor neuropathy, with persistent conduction block
- motor weakness
  - chronic inflammatory demyelinating polyneuropathy 73
  - Guillain–Barré syndrome 33, 34
  - inflammatory myopathies 244, 245–6
  - Lambert–Eaton myasthenic syndrome 148–9
  - myasthenia gravis 177–8
- multifocal motor neuropathy, with persistent conduction block 74–5, 76
  - anti-GM1 antibodies 80, 84, 139
  - differential diagnosis 80
- multiple sclerosis 74, 80
- muscle
  - autoimmune diseases 235–50
  - opportunistic infections 266
- muscle action potential, compound (CMAP)
  - chronic inflammatory demyelinating polyneuropathy 76, 78, 79
  - demyelinating neuropathies 42, 43
  - Guillain–Barré syndrome 45–7, 51
  - Lambert–Eaton myasthenic syndrome 149
- muscle fibres
  - antigen presentation 243–4
  - heat shock protein expression 240–1
  - MHC class I expression 269, 271, 272
  - T cell-mediated injury 239
  - in vitro* models 241–4
  - virological studies in HIV infection 260–3
- muscle-like cells, thymic 176
- muscle weakness, *see* motor weakness
- myasthenia gravis (MG) 2, 3, 165–95
  - anti-AChR antibody-negative 173–4
  - associated diseases 177
  - clinical features 177–8
  - diagnostic testing 178–9
  - experimental model, *see* experimental autoimmune myasthenia gravis
  - experimental therapeutic approaches 190–5
    - targeting antigen-specific T cell receptors 193–5
    - targeting B cells 191
    - T cell-directed 191–3
  - heterogeneity of anti-AChR antibodies 173, 225–8
  - HIV infection 258–9
  - humoral pathogenesis 169–74
    - see also* anti-acetylcholine receptor (AChR) antibodies
  - neuromuscular junction in 166–7
  - role of T cells 174–5
  - role of thymus 175–7
  - severity
    - anti-AChR antibodies and 171–2,

## INDEX

- 210–12
  - factors affecting 209–10
  - treatment 179–90
    - anti-cholinesterases 179–80
    - short-term immunotherapies 188–90
    - standard immunotherapy 181–8
    - thymectomy 180
- myasthenic syndrome, Lambert–Eaton, *see* Lambert–Eaton myasthenic syndrome
- myelin
  - autoimmune B cell responses 136–7
  - autoimmune responses in human disease 137–9
  - composition and molecular organization 8–10, 125–8
  - lipids 8–9, 56, 57, 128
  - proteins 9–10, 126–8
  - T cell-mediated autoimmune responses 130–3
  - widening of lamellae 12–13
- myelin-associated glycoprotein (MAG)
  - 9–10, 128
  - carbohydrate epitope 17–18
  - paraproteinaemic polyneuropathy and 19–20
  - see also* anti-myelin-associated glycoprotein (MAG) antibodies
- myelin basic protein (MBP) 9, 126–8
  - T cell-mediated autoimmune response 130
- myelin oligodendrocyte glycoprotein (MOG) 85
- myoblasts
  - antigen presentation 243
  - cytotoxic T cell-mediated lysis 242–3
  - HIV infection 263
  - HLA and adhesion molecule expression 241, 242
  - isolation 241
- myoglobinuria, HIV infection 258
- myoid cells, thymic 176
- myopathies, inflammatory, *see* inflammatory myopathies
- myosin, anti-AChR antibody reactivity 225–8
- myotubes 241
  - cytotoxic T cell-mediated lysis 242–3
  - HIV infection 263, 264
  - HLA and adhesion molecule expression 241, 242
  - HTLV-I infection 268, 270
  - natural killer cell-mediated lysis 244
- natural killer (NK) cells
  - inflammatory myopathies 236, 238
  - myotube lysis *in vitro* 244
- nemaline bodies 257–8
- nerve action potential (NAP) 77, 79
- nerve biopsy 113
- nerve conduction
  - block, *see* conduction block
  - slowing 41
  - temperature effects 42
- nerve conduction studies
  - chronic inflammatory demyelinating polyneuropathy 77–8
  - demyelinating neuropathies 40–2
  - Guillain–Barré syndrome 44–7, 48, 49–50, 51
  - vasculitic neuropathy 112–13
- nerve fibres
  - demyelination of large versus small 44
  - ectopic excitation 42
- nerve stimulation, repetitive 178
- neuromuscular junction, damage in
  - myasthenia gravis 171
- neuromuscular transmission
  - Lambert–Eaton myasthenic syndrome 150–1
  - myasthenia gravis 166–7
- neuromyotonia, acquired (Isaac's syndrome; NMT) 147, 158–60
  - aetiology 160
- neutrophils, vasculitic neuropathy 107, 109
- non-steroidal anti-inflammatory drugs (NSAIDs) 283
- onion bulbs 11, 82, 83
- P0 glycoprotein 9, 126, 127
  - carbohydrate epitope 17–18
  - Guillain–Barré syndrome and 56, 61
  - molecular mimicry and 68
  - paraproteinaemic polyneuropathy and 19, 20
  - T cell-mediated autoimmune response 130, 131
- P2 protein 9, 126–8
  - Guillain–Barré syndrome and 20, 21–2, 56, 61
  - pretreatment, experimental allergic neuritis 136
  - T cell-mediated autoimmune response 130–3, 138
- painful sensory neuropathy (PSN), HIV infection 278–9, 280, 284
- paraneoplastic disorders 148
- paraproteinaemic polyneuropathy (PPN; PAN) 7, 10–20, 76
  - animal model 123
  - clinical aspects 10–11
  - management 13–14
  - with monoclonal IgM (M-IgM)/anti-MAG antibodies 10–11, 128
  - pathogenesis 14–20, 138–9
  - pathology 11–13
- passive transfer studies

## IMMUNOLOGY OF NEUROMUSCULAR DISEASE

- acquired neuromyotonia 160
- chronic inflammatory demyelinating polyneuropathy 84–5, 138
- experimental allergic neuritis 130, 131
- experimental autoimmune myasthenia gravis 215, 218–19
- Guillain–Barré syndrome 138
- Lambert–Eaton myasthenic syndrome 151–2, 153–4
- myasthenia gravis 169
- penicillamine
  - myasthenia gravis induced by 177, 179
  - neuromyotonia induced by 160
- pericytes 124–5, 134
- peripheral nervous system (PNS)
  - autoimmune-mediated diseases 123–39
  - immune reactivity 124–5
- physical therapy, Guillain–Barré syndrome 72
- plasmapheresis
  - acquired neuromyotonia 159, 160
  - chronic inflammatory demyelinating polyneuropathy 85, 86–7, 88
  - Guillain–Barré syndrome 69–70, 71, 72
  - inflammatory myopathies 248
  - myasthenia gravis 188–9, 190
  - paraproteinaemic polyneuropathy 13–14
- POEMS syndrome 74
- polyarteritis nodosa 117
- polymyositis (PM) 235, 249–50
  - clinical features 244–5
  - differential diagnosis 246, 247
  - HIV infection, *see* HIV myopathy
  - HTLV-I 245, 267–9, 273
  - management 246–8
  - pathogenesis 237–41
  - retroviruses and 245, 273
- polyradiculoneuropathy, HIV infection 278, 279–80, 284
- potassium channel, voltage-gated (VGKC) 147, 160
- pyomyositis
  - HIV infection 259
  - management 283–4
- pyridostigmine bromide 179–80
- rabies vaccination 40
- ragged-red fibres 274, 275
- retroviruses 255–84
  - endogenous 273
  - polymyositis and 245, 273
  - see also* HIV infection
- ricin 191
- rods (nemaline bodies) 257–8
- Schwann cells 62, 125
- self-tolerance 1–4
- sensory deficits
  - chronic inflammatory demyelinating polyneuropathy 73
  - Guillain–Barré syndrome 33, 34
  - paraproteinaemic polyneuropathy 10–11
- sensory neuropathy
  - chronic ataxic 75–6
  - painful (PSN), HIV infection 278–9, 280, 284
- simian immunodeficiency virus (SIV) 272–3
- simian retrovirus type I (SRV-I) 272–3
- skin rash, dermatomyositis 244
- small cell lung cancer, *see* lung cancer, small cell
- somatosensory evoked potentials (SEP) 45
- Staphylococcus aureus* 259
- steroid myopathy 246–7
- steroids, *see* corticosteroids
- subacute idiopathic demyelinating polyradiculoneuropathy 37–8
- sulphated glucuronyl lactosaminyl paragloboside (SGLPG) 8, 9
  - paraproteinaemic polyneuropathy and 19, 20
- sulphated glucuronyl paragloboside (SGPG) 8, 9
  - carbohydrate epitope 17
  - Guillain–Barré syndrome (GBS) and 22, 58
  - paraproteinaemic polyneuropathy and 19, 20, 138–9
- sulphatide 8
  - chronic inflammatory demyelinating polyneuropathy and 23, 58
  - Guillain–Barré syndrome and 21–2, 58
- superantigens 4, 67
- synaptic vesicle proteins 158
- synaptotagmin 158
- systemic lupus erythematosus (SLE) 2, 3
- tachycardia, Guillain–Barré syndrome 37
- T cell receptors (TCR)
  - experimental allergic neuritis and 136
  - inflammatory myopathies 239
  - therapy of myasthenia gravis and 193–5
- T cells
  - autoimmune 2–4, 124–5
  - autoimmune responses to myelin 130–3, 138
  - chronic inflammatory demyelinating polyneuropathy 82, 85
  - dermatomyositis 236
  - experimental allergic neuritis 60–1, 62, 130, 131–4, 138
  - experimental autoimmune myasthenia gravis 221–3
  - $\gamma/\delta$  expressing, inflammatory myopathies 240–1
  - Guillain–Barré syndrome 60–2, 66, 67, 68



## INDEX

- inflammatory myopathies 236, 237–44
- myasthenia gravis 3, 174–5, 176
- penetration of blood–nerve barrier 124
- retrovirus-associated myopathies 263–6, 269, 271
- targeting, myasthenia gravis therapy 191–3
- vasculitis neuropathy 110
  - see also* CD4<sup>+</sup> T cells; CD8<sup>+</sup> T cells
- 'T cell vaccination' 193–4
- temperature, nerve conduction and 42
- temporal arteritis 110
- Tensilon test 149, 178
- thymectomy 176, 180
- thymomas 176, 180
- thymus gland
  - antibody-negative myasthenia gravis 174
  - role in myasthenia gravis 175–7
- Torpedo* electric organ 168
- tropical spastic paraparesis (TSP) 267
- d*-tubocurarine 158, 159, 160
- $\beta$ -tubulin 56
- tumour necrosis factor- $\alpha$  (TNF- $\alpha$ )
  - Guillain–Barré syndrome 62, 66, 67
  - myoblast/myotube responses 241, 242, 243
- Uhthoff's phenomenon 42
- uraemic neuropathy 80
- vaccination
  - Guillain–Barré syndrome and 40
  - 'T cell' 193–4
- varicella zoster virus 68
- vasculitic neuropathy 105–19
  - classification 114–15
  - clinical presentation 111–12
  - definition 105–6
  - diagnosis 112–14
  - epidemiology 105–6
  - future therapies 117–19
  - pathogenesis 106–10
  - pathology 110–11
  - prognosis 116–17
  - treatment 115–16
- voltage-gated calcium channels, *see* calcium channels, voltage-gated
- voltage-gated potassium channel (VGKC) 147, 160
- Waldenström's macroglobulinaemia 10
- Wegener's granulomatosis 109, 110, 117
- Wistar Furth (WF) rats, experimental autoimmune myasthenia gravis 214–17
- zidovudine, *see* azidothymidine

## Immunology and Medicine Series

---

1. A.M. McGregor (ed.). *Immunology of Endocrine Diseases*. 1986 ISBN: 0-85200-963-1
2. L. Ivanyi (ed.). *Immunological Aspects of Oral Diseases*. 1986 ISBN: 0-85200-961-5
3. M.A.H. French (ed.). *Immunoglobulins in Health and Disease*. 1986 ISBN: 0-85200-962-3
4. K. Whaley (ed.). *Complement in Health and Disease*. 1987 ISBN: 0-85200-954-2
5. G.R.D. Catto (ed.). *Clinical Transplantation: Current Practice and Future Prospects*. 1987 ISBN: 0-85200-960-7
6. V.S. Byers and R.W. Baldwin (ed.). *Immunology of Malignant Diseases*. 1987 ISBN: 0-85200-964-X
7. S.T. Holgate (ed.). *Mast Cells, Mediators and Disease*. 1988 ISBN: 0-85200-968-2
8. D.J.M. Wright (ed.). *Immunology of Sexually Transmitted Diseases*. 1988 ISBN: 0-74620-087-0
9. A.D.B. Webster (ed.). *Immunodeficiency and Disease*. 1988 ISBN: 0-85200-688-8
10. C. Stern (ed.). *Immunology of Pregnancy and its Disorders*. 1989 ISBN: 0-7462-0065-X
11. M.S. Klempner, B. Styrts and J. Ho (ed.). *Phagocytes and Disease*. 1989 ISBN: 0-85200-842-2
12. A.J. Zuckerman (ed.). *Recent Developments in Prophylactic Immunization*. 1989 ISBN: 0-7923-8910-7
13. S. Lightman (ed.). *Immunology of Eye Disease*. 1989 ISBN: 0-7923-8908-5
14. T.J. Hamblin (ed.). *Immunotherapy of Disease*. 1990 ISBN: 0-7462-0045-5
15. D.B. Jones and D.H. Wright (eds.). *Lymphoproliferative Diseases*. 1990 ISBN: 0-85200-965-8
16. C.D. Pusey (ed.). *Immunology of Renal Diseases*. 1991 ISBN: 0-7923-8964-6
17. A.G. Bird (ed.). *Immunology of HIV Infection*. 1991 ISBN: 0-7923-8962-X
18. J.T. Whicher and S.W. Evans (eds.). *Biochemistry of Inflammation*. 1992 ISBN: 0-7923-8985-9
19. T.T. MacDonald (ed.). *Immunology of Gastrointestinal Diseases*. 1992 ISBN: 0-7923-8961-1
20. K. Whaley, M. Loos and J.M. Weiler (eds.). *Complement in Health and Disease, 2nd Edn*. 1993 ISBN: 0-7923-8823-2
21. H.C. Thomas and J. Waters (eds.). *Immunology of Liver Disease*. 1994 ISBN: 0-7923-8975-1
22. G.S. Panayi (ed.). *Immunology of Connective Tissue Diseases*. 1994 ISBN: 0-7923-8988-3
23. G. Scadding (ed.). *Immunology of ENT Disorders*. 1994 ISBN: 0-7923-8914-X